New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
09:23 EDTHALO, AMGN, PRAN, CRIS, SINA, MNKD, GRFS, ING, EXAS, LULUOn The Fly: Pre-market Movers
HIGHER: Lululemon (LULU), up 3% following upgrade at Wedbush... SINA (SINA), up 3.5% after upgraded at Pacific Crest... Grifols (GRFS), up 2.5% after announcing 7-year agreement with Japanese Red Cross... Exact Sciences (EXAS), up 3.6% after Barron's says shares could rise 50%... Curis (CRIS), up 11% after announcing removal of FDA partial clinical hold on CUDC-427... Halozyme (HALO), up 9% after announcing that trial of Hylenex recombinant met primary endpoint... ING (ING), up 4.5% after paying EUR1.23B to Dutch State... Amgen (AMGN), up 2% after AMG 145 reduced LDL cholesterol in statin intolerant patients... LOWER: Prana (PRAN), down 66% after Alzheimer's study doesn't hit targets... MannKind (MNKD), down 5.6% after downgraded at Piper Jaffray.
News For LULU;MNKD;PRAN;EXAS;SINA;AMGN;ING;CRIS;HALO;GRFS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 30, 2015
11:47 EDTMNKDMannKind's Afrezza lags behind in inhaled insulin market, The Street reports
The number of prescriptions written for MannKind's (MNKD) Afrezza is lagging behind in the diabetes market, reports The Street. This comes five months after Sanofi (SNY) launched the product. Afrezza is also under-performing Exubera, the first inhaled insulin launched by Pfizer (PFE) nine years ago. Reference Link
11:36 EDTAMGNRumor: Amgen moves up on speculation of an investor stake
Subscribe for More Information
10:00 EDTINGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:03 EDTAMGNCelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
06:00 EDTINGING Groep upgraded to Buy from Neutral at BofA/Merrill
June 29, 2015
06:47 EDTINGCredit Suisse, ING aiming to move some activities out of London, FT says
Subscribe for More Information
June 26, 2015
13:46 EDTEXASFly Watch: Exact Sciences predicted to jump if task force update favorable
The US Preventive Services Task Force, or USPSTF, is expected to publish its revised guidelines for colorectal cancer, or CRC, screening in the third quarter of 2015. The guidelines should include an assessment of Exact Sciences' (EXAS) Cologuard, an "easy to use, noninvasive colon cancer screening test." ANALYST TAKE: The USPSTF guidelines were noted as "the last binary event for Cologuard" by Jefferies and "the major overhang" for Exact Sciences by Mizuho Securities. Jefferies analyst Brandon Couillard and his team, which rate Exact Sciences a Buy with a $33 price target, see "significant upside" from a favorable outcome and said their thesis was boosted by confident comments from a "former affiliate of the USPSTF's review board." Mizuho analysts Peter Lawson and Eric Criscuolo, who rate Exact Sciences a Buy with a $35 price target, said they believe Cologuard will receive an "A" or "B" rating from the USPSTF, triggering further adoption by mandating coverage of Cologuard by private insurance. Baird defended Exact Sciences after the stock dropped 5.5% on Thursday, June 25, saying Exact Sciences' investor relations day was "bullish" in tone as the company provided a "deep dive" update on its Cologuard launch. Baird maintained its Outperform rating and $44 price target on the company. PRICE ACTION: Over the past week, shares of Exact Sciences are up more than 5% despite Thursday's 5.5% pullback. Over the last month, shares are up about 12% and over the last three months they are higher by almost 40%.
10:23 EDTLULUAnalyst warns lululemon seeing increased competition in Canada
lululemon's (LULU) Canadian stores will probably be under pressure as new competitors have entered the company's core yoga apparel market there, research firm Macquarie warned in a note to investors earlier today. The firm highlighted one such competitor, Lole's Learning. WHAT'S NEW: Canada based Lole’s Learning and lululemon have similar products, similar prices, similar marketing events and similar store locations, Macquarie analyst Laurent Vasilescu reported. However, Lole's prices are "a tad more competitive," the analyst stated. Lole's started out as a wholesaler, but now has about 2,000 retail locations, many of which are within walking distance of lululemon stores, the analyst stated. Lole's has grown at a compound annual growth rate of 29% over the last five years, according to Vasilescu, who kept a $42 price target and Underperform rating on lululemon. WHAT'S NOTABLE: On June 9, lululemon reported slightly stronger than expected first quarter results and said that its U.S. stores were posting strong same-store sales trends in the initial weeks of Q2, while its Canadian stores were seeing positive Q2 comp trends. PRICE ACTION: In early trading, lululemon rose 1% to $68.29.
08:18 EDTEXASExact Sciences recent weakness unwarranted, says Baird
Subscribe for More Information
07:17 EDTEXASExact Sciences compelling as a platform growth company, says Canaccord
Subscribe for More Information
June 25, 2015
14:02 EDTGRFSGrifols initiated with a Buy at HSBC
Subscribe for More Information
10:19 EDTLULUlululemon recalling women's tops with elastic draw cords due to injury hazard
Subscribe for More Information
08:03 EDTEXASExact Sciences to host analyst and investor day with a conference call hookup
Subscribe for More Information
06:34 EDTEXASExact Sciences' Cologuard shows strong sales in Q2
Subscribe for More Information
June 24, 2015
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information
June 23, 2015
07:25 EDTAMGNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
12:13 EDTSINAMorgan Stanley reports 5.0% passive stake in SINA
Subscribe for More Information
07:53 EDTEXASExact Sciences estimates raised ahead of analyst Day at Canaccord
Canaccord raised its estimates on Exact Sciences ahead of June 26 Analyst Day. The firm cited the impact from the 160-person sales force addition from Ironwood Pharmaceuticals and pipeline opportunities beyond Cologuard for the increase. Canaccord raised its price target to $32 from $30 on Exact Sciences shares.
07:45 EDTHALOHalozyme price target raised to $25 from $20 at JPMorgan
JPMorgan raised its price target for Halozyme to $25 after speaking with CEO Hellen Torley. The firm remains positive on the potential for PEGPH20 and keeps an Overweight rating on the stock.
06:02 EDTLULUStocks with implied volatility below IV index mean; QIHU LULU
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use